Stephen Furlong Sells 17,307 Shares of Neuronetics, Inc. (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 17,307 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $4.11, for a total value of $71,131.77. Following the completion of the sale, the chief financial officer now directly owns 454,420 shares in the company, valued at $1,867,666.20. This trade represents a 3.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Stephen Furlong also recently made the following trade(s):

• On Wednesday, February 12th, Stephen Furlong sold 10,845 shares of Neuronetics stock. The shares were sold at an average price of $3.83, for a total value of $41,536.35.
• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The shares were sold at an average price of $3.28, for a total value of $48,662.08.

Neuronetics Stock Performance

NASDAQ:STIM opened at $4.46 on Thursday. The stock’s 50-day simple moving average is $2.41 and its 200 day simple moving average is $1.47. The firm has a market capitalization of $135.36 million, a PE ratio of -3.63 and a beta of 2.17. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. Neuronetics, Inc. has a twelve month low of $0.52 and a twelve month high of $5.07.

Institutional Trading of Neuronetics

Several large investors have recently bought and sold shares of the business. Tradewinds LLC. acquired a new stake in shares of Neuronetics during the fourth quarter valued at about $32,000. XTX Topco Ltd acquired a new stake in shares of Neuronetics during the fourth quarter valued at about $49,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Neuronetics during the third quarter valued at about $53,000. GSA Capital Partners LLP boosted its stake in shares of Neuronetics by 64.5% during the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock valued at $60,000 after purchasing an additional 30,837 shares in the last quarter. Finally, David J Yvars Group boosted its stake in shares of Neuronetics by 47.1% during the fourth quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after purchasing an additional 14,825 shares in the last quarter. 53.59% of the stock is owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.